Clinical trial NCT03955224: Evaluation of Low-Level Laser Therapy Efficacy in Pain Management of Grade 2 Oral Mucositis Induced by Radiotherapy or Chemoradiotherapy: a Study in Patients With Upper Aerodigestive Tract Cancer
Official title: Evaluation of Low-Level Laser Therapy Efficacy in Pain Management of Grade 2 Oral Mucositis Induced by Radiotherapy or Chemoradiotherapy: a Phase II Randomized Study in Patients With Upper Aerodigestive Tract Cancer
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE2
Conditions: Upper Aerodigestive Tract Neoplasms
Keywords: Upper Aerodigestive Tract Neoplasms
Low-Level Laser Therapy (LLLT)
Mucositis
Lead sponsor: Institut Claudius Regaud
Sponsor class: OTHER
First posted: 2019-05-20
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Prospective, monocentric, randomized phase II study evaluating Low-Level Laser Therapy (LLLT) as a treatment for the pain due to grade 2 oral mucositis in patients with upper aero-digestive tract cancer treated by radiotherapy or chemoradiotherapy.

Patients with upper aero-digestive tract cancer receiving their first cervicofacial radiotherapy or chemoradiotherapy will be included in this study if they suffer from oral mucositis due to their treatment.

The study procedure will consist in 5 applications of the LLLT that will be performed at three days intervals for a maximum duration of 15 days.

Each patient will be followed until 3 days after the end of the study treatment, for a total duration of the study of 18 days.


Eligibility criteria: Inclusion Criteria:

1. Age ≥ 18 years.
2. Patients with upper aero-digestive tract cancer receiving a first cervicofacial radiotherapy or chemoradiotherapy
3. Patients with a grade 2 mucositis (according to the NCI CTCAE version 5.0) appearing during treatment.
4. Patients available to perform the LLLT treatment: 5 visits at 3 days intervals
5. Patients must provide written informed consent prior to any study specific procedures.
6. Patients affiliated to a Social Health Insurance in France.

Exclusion Criteria:

1. Patients who have already received a cervicofacial radiotherapy
2. Patients who have already received an induction chemotherapy for their upper aero-digestive tract cancer
3. Patients under targeted therapy for their upper aero-digestive tract cancer
4. Patients under systemic corticotherapy
5. Patients with a non-grade 2 mucositis (according to the NCI CTCAE version 5.0)
6. Patients with ulceration or any other oral mucosa pathology than mucositis
7. Pregnant or breastfeeding women
8. Any psychological, familial, geographical or sociological condition which does not allow to respect the medical follow-up and/or compliance to study procedure
9. Patient who has forfeited his/her freedom by administrative or legal award or who is under legal protection (curatorship and guardianship, protection of justice)

Primary outcomes:
measure: Rate of patients who didn't need a dose increase or introduction of new analgesics for mouth pain during the study compared to baseline
timeFrame: 16 days for each patient
Secondary outcomes:
measure: Evaluation of the oral mucositis pain intensity with Visual Analog Scale Scores
timeFrame: 16 days for each patient
measure: Quality of Life assessed by the Quality of Life Questionnaire specific to Head and Neck cancer (H&N35)
timeFrame: 16 days for each patient
measure: Frequency of adverse events related to the LLLT using the National Cancer Institute Common Toxicity Criteria for Adverse Effects (NCI CTCAE) version 5.0
timeFrame: 16 days for each patient
Other outcomes:
Locations:
city: Toulouse
country: France
facility: Institut Universitaire du Cancer de Toulouse - Oncopole
Study officials:
References: